David M Keeling

List of Publications by Year
in descending order

56 papers	5,007 citations	249298 26 h-index	206121 51 g-index
59 all docs	59 docs citations	59 times ranked	5092 citing authors

#	Article	IF	Citations
1	Nextâ€generation sequencing for the diagnosis ofMYH9â€RD: Predicting pathogenic variants. Human Mutation, 2020, 41, 277-290.	1.1	30
2	The use of artificial neural network analysis can improve the riskâ€stratification of patients presenting with suspected deep vein thrombosis. British Journal of Haematology, 2019, 185, 289-296.	1.2	22
3	Reducing the need for diagnostic imaging in suspected cases of deep vein thrombosis. British Journal of Haematology, 2019, 184, 682-684.	1.2	2
4	Stockings to prevent post-thrombotic syndromeâ€"where are we now?. Lancet Haematology,the, 2018, 5, e4-e5.	2.2	1
5	Idarucizumab for dabigatran overdose in a child. British Journal of Haematology, 2018, 180, 457-459.	1.2	22
6	The aspirin story â€“ from willow to wonder drug. British Journal of Haematology, 2017, 177, 674-683.	1.2	219
7	Unexpected haemophilia despite pre-natal testing - a combined haemophilia A and haemophilia B family. British Journal of Haematology, 2017, 179, 182-182.	1.2	0
8	Periâ€operative management of anticoagulation and antiplatelet therapy. British Journal of Haematology, 2016, 175, 602-613.	1.2	159
9	Is there a benefit in computed tomography screening for cancer in patients with unprovoked proximal deep venous thrombosis? A cohort study in the Oxford University Hospitals <scp>NHS</scp> Trust. British Journal of Haematology, 2016, 172, 978-979.	1.2	3
10	Controversies in venous thromboembolism â€" 2015. Blood Reviews, 2016, 30, 27-33.	2.8	8
11	Prediction of Bleeding Risk in Patients on Extended Oral Anticoagulation for Venous Thromboembolism. Blood, 2016, 128, 139-139.	0.6	3
12	Management of an uncommon form of type 2M VWD: a single centre experience. The Journal of Haemophilia Practice, 2016, 3, 47-50.	0.2	1
13	Do Genetic Contributors to Warfarin Responsiveness or Common Thrombophilias Influence the Risk of Major Bleeding in Patients on Extended Duration Vitamin K Antagonist (VKA) for Venous Thromboembolic Disease?. Blood, 2016, 128, 272-272.	0.6	0
14	Effect of age on factor <scp>IX</scp> levels in symptomatic carriers of Haemophila B Leyden. British Journal of Haematology, 2015, 169, 448-449.	1.2	9
15	Guideline on aspects of cancerâ€related venous thrombosis. British Journal of Haematology, 2015, 170, 640-648.	1.2	139
16	A practical guideline for the haematological management of major haemorrhage. British Journal of Haematology, 2015, 170, 788-803.	1.2	202
17	Venous thromboembolism: risk of recurrence and long-term anticoagulation. British Journal of Hospital Medicine (London, England: 2005), 2015, 76, 72-77.	0.2	2
18	Patient selfâ€testing and selfâ€management of oral anticoagulation with vitamin <scp>K</scp> antagonists: guidance from the <scp>B</scp>ritish <scp>C</scp>ommittee for <scp>S</scp>tandards in <scp>H</scp>aematology. British Journal of Haematology, 2014, 167, 600-607.	1.2	26

#	Article	IF	Citations
19	Authorsâ€™ response. British Journal of Ophthalmology, 2014, 98, 1136-1137.	2.1	0
20	The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emergency Medicine Journal, 2014, 31, 163-168.	0.4	64
21	Activated prothrombin complex concentrate for the prevention of dabigatranâ€•associated bleeding. British Journal of Haematology, 2014, 166, 152-153.	1.2	22
22	The diagnosis and management of von <scp>W</scp>illebrand disease: a <scp>U</scp>nited <scp>K</scp>ingdom <scp>H</scp>aemophilia <scp>C</scp>entre <scp>D</scp>octors <scp>O</scp>rganization guideline approved by the <scp>B</scp>ritish <scp>C</scp>ommittee for <scp>S</scp>tandards in <scp>H</scp>aematology. British Journal of Haematology, 2014, 167, 453-465.	1.2	297
23	Diagnosis and management of heritable thrombophilias. BMJ, The, 2014, 349, g4387-g4387.	3.0	45
24	Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery. British Journal of Ophthalmology, 2014, 98, 1320-1324.	2.1	42
25	Management of bleeding in patients taking <scp>FX</scp>a and <scp>FII</scp>a inhibitors. British Journal of Haematology, 2013, 160, 1-2.	1.2	6
26	Management of venous thromboembolism â€“ controversies and the future. British Journal of Haematology, 2013, 161, 755-763.	1.2	8
27	How to interpret a prolonged prothrombin time or activated partial thromboplastin time. British Journal of Hospital Medicine (London, England: 2005), 2013, 74, C10-C12.	0.2	4
28	The use of age-dependent D-dimer cut-off values to exclude deep vein thrombosis. Reply to "Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded". Haematologica 2012;97(10):1507-13. Haematologica, 2012, 97, e43-e44.	1.7	8
29	Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology. British Journal of Haematology, 2012, 159, 427-429.	1.2	148
30	Guidelines on the investigation and management of venous thrombosis at unusual sites. British Journal of Haematology, 2012, 159, 28-38.	1.2	119
31	Guidelines on the diagnosis and management of heparinâ€•induced thrombocytopenia: second edition. British Journal of Haematology, 2012, 159, 528-540.	1.2	179
32	Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology, 2012, 157, 47-58.	1.2	492
33	Guidelines on oral anticoagulation with warfarin â€“ fourth edition. British Journal of Haematology, 2011, 154, 311-324.	1.2	482
34	Thrombophilia screening or screaming. Journal of Thrombosis and Haemostasis, 2010, 8, 1191-1192.	1.9	4
35	Clinical guidelines for testing for heritable thrombophilia. British Journal of Haematology, 2010, 149, 209-220.	1.2	434
36	Von Willebrand disease, angiodysplasia and atorvastatin. British Journal of Haematology, 2010, 149, 159-160.	1.2	22

#	Article	IF	Citations
37	The story of the discovery of heparin and warfarin. British Journal of Haematology, 2008, 141, 757-763.	1.2	274
38	Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood, 2007, 109, 1870-1877.	0.6	646
39	Efficacy of Warfarin Reversal in Orthopedic Trauma Surgery Patients. Journal of Orthopaedic Trauma, 2007, 21, 26-30.	0.7	33
40	The management of heparin-induced thrombocytopenia. British Journal of Haematology, 2006, 133, 259-269.	1.2	184
41	Reversal of asymptomatic over-anticoagulation by orally administered vitamin K. British Journal of Haematology, 2006, 133, 331-336.	1.2	26
42	The use of rituximab in two children with allo-antibodies towards factor VIII. British Journal of Haematology, 2006, 133, 214-216.	1.2	10
43	The management of heparin-induced thrombocytopenia. British Journal of Haematology, 2006, 135, 269-269.	1.2	59
44	Duration of anticoagulation: decision making based on absolute risk. Blood Reviews, 2006, 20, 173-178.	2.8	19
45	An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thrombosis and Haemostasis, 2006, 96, 630-41.	1.8	62
46	The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype. British Journal of Haematology, 2005, 128, 830-836.	1.2	28
47	A simple inhibitor screen is more sensitive than a Bethesda assay in monitoring for the development of inhibitors in haemophilia A and B. British Journal of Haematology, 2005, 128, 885-885.	1.2	21
48	Hormone replacement therapy, thrombosis and thrombophilia. The Journal of the British Menopause Society, 2005, 11, 74-75.	1.3	0
49	The diagnosis of deep vein thrombosis in symptomatic outpatients and the potential for clinical assessment and D-dimer assays to reduce the need for diagnostic imaging. British Journal of Haematology, 2004, 124, 15-25.	1.2	82
50	Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. Blood Coagulation and Fibrinolysis, 2004, 15, 503-504.	0.5	30
51	Relation between acute hypoxia and activation of coagulation in human beings. Lancet, The, 2003, 361, 2207-2208.	6.3	82
52	Combined oral contraceptives and the risk of myocardial infarction. Annals of Medicine, 2003, 35, 413-418.	1.5	21
53	Normal d-dimer levels do not exclude the diagnosis of cerebral venous sinus thrombosis. Journal of Neurology, 2002, 249, 1603-1604.	1.8	27
54	â€˜Sagittal sinus thrombosis in a teenager: homocystinuria associated with reversible antithrombin deficiencyâ€™. Developmental Medicine and Child Neurology, 2002, 44, 498-498.	1.1	4

#	Article	IF	Citations
55	Laboratory monitoring of antiplatelet therapy. , 2001, , 386-406.		1
56	Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. British Journal of Haematology, 1998, 101, 483-486.	1.2	172